Shots:

• The approval is based on REFLECTIONS B7391003 study results assessing Zirabev vs reference product Avastin- in patients with advanced non-sq NSCLC
• The study resulted in biosimilarity data- showing clinical equivalence and no clinically meaningful differences with the reference product in patients. Additionally- Zirabev is Pfizer’s second oncology biosimilar following Trazimera (trastuzumab-qyyp)
• Zirabev (bevacizumab-bvzr) is a mAb inhibits formation of new blood cells (angiogenesis) approved by the US FDA for MCC- unresectable/LA/recurrent or mnon-sq NSCLC- recurrent glioblastoma- mRCC- and persistent- recurrent or metastatic cervical cancer

Click here to read full press release/ article | Ref: Pfizer | Image: The Hans India